The Experts below are selected from a list of 198759 Experts worldwide ranked by ideXlab platform
Jelle O Barentsz - One of the best experts on this subject based on the ideXlab platform.
-
transition zone prostate Cancer Detection and localization with 3 t multiparametric mr imaging
Radiology, 2013Co-Authors: Caroline M A Hoeks, Thomas Hambrock, Derya Yakar, Ton Feuth, Alfred J Witjes, Jurgen J Futterer, Jelle O BarentszAbstract:PURPOSE: To retrospectively compare transition zone (TZ) Cancer Detection and localization accuracy of 3-T T2-weighted magnetic resonance (MR) imaging with that of multiparametric (MP) MR imaging, with radical prostatectomy specimens as the reference standard. MATERIALS AND METHODS: The informed consent requirement was waived by the institutional review board. Inclusion criteria were radical prostatectomy specimen TZ Cancer larger than 0.5 cm(3) and 3-T endorectal presurgery MP MR imaging (T2-weighted imaging, diffusion-weighted [DW] imaging apparent diffusion coefficient [ADC] maps [b .05). CONCLUSION: Use of 3-T MP MR imaging, consisting of T2-weighted imaging, DW imaging ADC maps (b values, 50, 500, and 800 sec/mm(2)), and DCE MR imaging may not improve TZ Cancer Detection and localization accuracy compared with T2-weighted imaging. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.12120281/-/DC1.
-
transition zone prostate Cancer Detection and localization with 3 t multiparametric mr imaging
Radiology, 2013Co-Authors: Caroline M A Hoeks, Thomas Hambrock, Derya Yakar, Ton Feuth, Alfred J Witjes, Jurgen J Futterer, Christina Hulsbergenvan A De Kaa, Jelle O BarentszAbstract:Use of 3-T multiparametric MR imaging, consisting of T2-weighted imaging, low-b- value (<1000 sec/mm2) diffusion-weighted apparent diffusion coefficient mapping, and dynamic contrast material–enhanced MR imaging, may not improve transition zone Cancer Detection and localization accuracy compared with those attained with 3-T T2-weighted imaging alone.
F Cornud - One of the best experts on this subject based on the ideXlab platform.
-
prebiopsy magnetic resonance imaging and prostate Cancer Detection comparison of random and targeted biopsies
The Journal of Urology, 2013Co-Authors: Nicolas Barry Delongchamps, Michael Peyromaure, Alexandre Schull, F Beuvon, Naim Bouazza, T Flam, Marc Zerbib, Naira Muradyan, P Legman, F CornudAbstract:Purpose: We compared the accuracy of visual targeted biopsies vs computerized transrectal ultrasound-magnetic resonance imaging registration using a rigid (Esaote®, nondeformable) or elastic (Koelis®, deformable) approach.Materials and Methods: A total of 391 consecutive patients with suspected localized prostate Cancer were prospectively included in analysis. All patients underwent prostate magnetic resonance imaging, followed by 10 to 12-core random prostate biopsies. When magnetic resonance imaging detected suspicious findings, targeted biopsy was performed, including visual, rigid system and elastic system targeted biopsies in the first 127 patients, the next 131 and the last 133, respectively. Cancer Detection rates were assessed by conditional logistic regression. Targeted biopsies alone and random biopsies were further compared for the amount of tissue sampled and microfocal Cancer Detection, the latter defined as a single core with 5 mm or less of Gleason 6 Cancer.Results: Patient characteristics ...
-
prebiopsy magnetic resonance imaging and prostate Cancer Detection comparison of random and targeted biopsies
The Journal of Urology, 2013Co-Authors: Nicolas Barry Delongchamps, Michael Peyromaure, Alexandre Schull, F Beuvon, Naim Bouazza, T Flam, Marc Zerbib, Naira Muradyan, P Legman, F CornudAbstract:Purpose: We compared the accuracy of visual targeted biopsies vs computerized transrectal ultrasound-magnetic resonance imaging registration using a rigid (Esaote®, nondeformable) or elastic (Koelis®, deformable) approach.Materials and Methods: A total of 391 consecutive patients with suspected localized prostate Cancer were prospectively included in analysis. All patients underwent prostate magnetic resonance imaging, followed by 10 to 12-core random prostate biopsies. When magnetic resonance imaging detected suspicious findings, targeted biopsy was performed, including visual, rigid system and elastic system targeted biopsies in the first 127 patients, the next 131 and the last 133, respectively. Cancer Detection rates were assessed by conditional logistic regression. Targeted biopsies alone and random biopsies were further compared for the amount of tissue sampled and microfocal Cancer Detection, the latter defined as a single core with 5 mm or less of Gleason 6 Cancer.Results: Patient characteristics ...
William J. Catalona - One of the best experts on this subject based on the ideXlab platform.
-
a prospective randomized trial comparing 6 versus 12 prostate biopsy cores impact on Cancer Detection
The Journal of Urology, 2000Co-Authors: Cathy K Naughton, Douglas E Mager, David K. Ornstein, David C Miller, William J. CatalonaAbstract:Purpose: Several studies suggest that sextant transrectal ultrasound guided biopsy of the prostate provides insufficient material to detect all clinically important prostate Cancer, and obtaining more biopsy cores may improve the Cancer Detection rate. We performed a prospective randomized trial comparing 6 to 12 prostate biopsy cores to determine the impact on the Cancer Detection rate.Materials and Methods: We prospectively randomized 244 men, including 71 (29%) black men, with a mean age plus or minus standard deviation of 65 ± 8 years to undergo biopsy with 6 or 12 peripheral zone tissue cores. In our study subjects serum total prostate specific antigen (PSA) was between 2.5 and 20 ng./ml., and/or digital rectal examination was suspicious for Cancer. All men completed a self-administered pre-biopsy and 2 post-biopsy questionnaires at 2 and 4 weeks. Cancer Detection rates were compared in the groups and correlated with race, biopsy history, digital rectal examination findings, total PSA, transrectal ul...
-
comparison of percent free psa psa density and age specific psa cutoffs for prostate Cancer Detection and staging
Urology, 2000Co-Authors: William J. Catalona, Paula C Southwick, Kevin M Slawin, Alan W Partin, Michael K Brawer, Robert C Flanigan, Anup Patel, Jerome P Richie, Patrick C Walsh, Peter T ScardinoAbstract:Abstract Objectives. Various methods have been proposed to increase the specificity of prostate-specific antigen (PSA), including age-specific PSA reference ranges, PSA density (PSAD), and percent free PSA (%fPSA). In this multicenter study, we compared these methods for their utility in Cancer Detection and their ability to predict pathologic stage after radical prostatectomy in patients with clinically localized, Stage T1c Cancer. Methods. Seven hundred seventy-three men (379 with prostate Cancer, 394 with benign prostatic disease), 50 to 75 years old, from seven medical centers were enrolled in this prospective blinded study. All subjects had a palpably benign prostate, PSA 4.0 to 10.0 ng/mL, and a histologically confirmed diagnosis. Hybritech’s Tandem PSA and free PSA assays were used. Results. %fPSA and age-specific PSA cutoffs enhanced PSA specificity for Cancer Detection, but %fPSA maintained significantly higher sensitivities. Age-specific PSA cutoffs missed 20% to 60% of Cancers in men older than 60 years of age. %fPSA and PSAD performed equally well for Detection (95% sensitivity) if cutoffs of 25% fPSA or 0.078 PSAD were used. The commonly used PSAD cutoff of 0.15 detected only 59% of Cancers. %fPSA and PSAD also produced similar results for prediction of the post-radical prostatectomy pathologic stage. Patients with Cancer with higher %fPSA values (greater than 15%) or lower PSAD values (0.15 or less) tended to have less aggressive disease. Conclusions. The results of this study demonstrated that Cancer Detection (sensitivity) is significantly higher with %fPSA than with age-specific PSA reference ranges. %fPSA and PSAD provide comparable results, suggesting that %fPSA may be used in place of PSAD for biopsy decisions and in algorithms for prediction of less aggressive tumors since the determination of %fPSA does not require ultrasound.
Caroline M A Hoeks - One of the best experts on this subject based on the ideXlab platform.
-
transition zone prostate Cancer Detection and localization with 3 t multiparametric mr imaging
Radiology, 2013Co-Authors: Caroline M A Hoeks, Thomas Hambrock, Derya Yakar, Ton Feuth, Alfred J Witjes, Jurgen J Futterer, Jelle O BarentszAbstract:PURPOSE: To retrospectively compare transition zone (TZ) Cancer Detection and localization accuracy of 3-T T2-weighted magnetic resonance (MR) imaging with that of multiparametric (MP) MR imaging, with radical prostatectomy specimens as the reference standard. MATERIALS AND METHODS: The informed consent requirement was waived by the institutional review board. Inclusion criteria were radical prostatectomy specimen TZ Cancer larger than 0.5 cm(3) and 3-T endorectal presurgery MP MR imaging (T2-weighted imaging, diffusion-weighted [DW] imaging apparent diffusion coefficient [ADC] maps [b .05). CONCLUSION: Use of 3-T MP MR imaging, consisting of T2-weighted imaging, DW imaging ADC maps (b values, 50, 500, and 800 sec/mm(2)), and DCE MR imaging may not improve TZ Cancer Detection and localization accuracy compared with T2-weighted imaging. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.12120281/-/DC1.
-
transition zone prostate Cancer Detection and localization with 3 t multiparametric mr imaging
Radiology, 2013Co-Authors: Caroline M A Hoeks, Thomas Hambrock, Derya Yakar, Ton Feuth, Alfred J Witjes, Jurgen J Futterer, Christina Hulsbergenvan A De Kaa, Jelle O BarentszAbstract:Use of 3-T multiparametric MR imaging, consisting of T2-weighted imaging, low-b- value (<1000 sec/mm2) diffusion-weighted apparent diffusion coefficient mapping, and dynamic contrast material–enhanced MR imaging, may not improve transition zone Cancer Detection and localization accuracy compared with those attained with 3-T T2-weighted imaging alone.
Stephen J Jones - One of the best experts on this subject based on the ideXlab platform.
-
type of transrectal ultrasonography probe influences prostate Cancer Detection rates on repeat prostate biopsy
BJUI, 2012Co-Authors: Christina Ching, Osama Zaytoun, Ayman S Moussa, Anthony Avallone, Stephen J JonesAbstract:Study Type – Diagnostic (case series) Level of Evidence 4 What's known on the subject? and What does the study add? It is known that the end-fire probe detects more prostate Cancer on initial prostate biopsy, but there is no literature looking at the influence of type of probe on repeat biopsy. Given that the literature on the influence of ultrasonography probe on repeat prostate biopsy is non-existent, the present study adds information which may help urologists improve their chances of detecting prostate Cancer on prostate biopsy. Determining which type of probe to use on a prostate biopsy is a simple external factor that may help improve patient management. OBJECTIVE • To determine if the type of transrectal ultrasonography (TRUS) probe used during repeat prostate biopsy influences prostate Cancer Detection rates. PATIENTS AND METHODS • We conducted a retrospective chart review of 680 men undergoing repeat prostate biopsy at our institution between 2000 and 2010. • Patient mean (range) age was 64.2 (39–95) years. • The median (range) prostate-specific antigen (PSA) level was 5.5 (0.37–33.8) ng/mL and median (range) free PSA was 17 (5–45) %. • Patient age, PSA, prostate volume, number of biopsy cores, time interval between initial and repeat biopsy, digital rectal examination and pathological findings were all included in a multivariate logistic regression analysis. RESULTS • The use of an end-fire probe on repeat biopsy significantly increased prostate Cancer Detection (odds ratio [OR] 1.59, 95% confidence interval [CI]: 1.03–2.46). • The time interval between 1st and 2nd biopsy was also significant (OR 1.46, 95% CI: 1.11–1.09). • On univariate analysis, white race (OR 0.66, 95% CI: 0.44–0.99), increasing prostate volume (OR 0.70, 95% CI: 0.55–0.89), and higher free PSA (OR 0.54, 95% CI: 0.34–0.84) were associated with a decreased risk of Cancer. • When evaluating the different permutations of using an end-fire or side-fire probe on initial or repeat biopsy, there was no difference in prostate Cancer Detection regardless of order of use of an end-fire or side-fire probe. CONCLUSIONS • An end-fire probe is associated with improved prostate Cancer Detection rates on both initial and repeat biopsy. • The order of probe use does not appear to matter.
-
does transrectal ultrasound probe configuration really matter end fire versus side fire probe prostate Cancer Detection rates
The Journal of Urology, 2009Co-Authors: Christina B Ching, Craig D Zippe, Ayman S Moussa, Jianbo Li, Brian R Lane, Stephen J JonesAbstract:Purpose: We compared prostate Cancer Detection rates for the 2 most commonly used transrectal ultrasound prostate biopsy probes, end fire and side fire, to determine whether the probe configuration affects Detection rates.Materials and Methods: We evaluated 2,674 patients who underwent initial prostate biopsy between 2000 and 2008 with respect to prostate specific antigen, biopsy technique and pathological findings. Patients were divided into 1,124 in whom biopsies were performed with an end fire probe and 1,550 in whom biopsies were performed with a side fire probe.Results: There was a significant difference in the overall Cancer Detection rate in the end vs side fire arms (45.8% vs 38.5%, p <0.001). In the subsets of patients with prostate specific antigen greater than 4 to 10 ng/ml or less and greater than 10 ng/ml a significant difference persisted (46.4% vs 38.9% and 61.7% vs 49.1%, p <0.004 and <0.015, respectively). There was also a significant difference in Detection rates between probes in those ...
-
saturation technique does not improve Cancer Detection as an initial prostate biopsy strategy
The Journal of Urology, 2006Co-Authors: Stephen J Jones, John Rabets, Craig D Zippe, Lynn Schoenfield, Amit Patel, Cristina MagigalluzziAbstract:Purpose: We reported on the results of a sequential cohort study comparing office based saturation prostate biopsy to traditional 10-core sampling as an initial biopsy.Materials and Methods: Based on improved Cancer Detection of office based saturation prostate biopsy repeat biopsy, we adopted the technique as an initial biopsy strategy to improve Cancer Detection. Two surgeons performed 24-core saturation prostate biopsies in 139 patients undergoing initial biopsy under periprostatic local anesthesia. Indication for biopsy was an increased PSA of 2.5 ng/dl or greater in all patients. Results were compared to those of 87 patients who had previously undergone 10-core initial biopsies.Results: Cancer was detected in 62 of 139 patients (44.6%) who underwent saturation biopsy and in 45 of 87 patients (51.7%) who underwent 10-core biopsy (p >0.9). Breakdown by PSA level failed to show benefit to the saturation technique for any degree PSA increase. Men with PSA 2.5 to 9.9 ng/dl were found to have Cancer in 53 ...
